Omthera Pharmaceuticals
IPO
- Headquarters
- Princeton, New Jersey
- Employees
- 1–10
- Founded
- 2009
- Business Model
- B2B
- Website
- omthera.com
- Total Funding
- $33.9M
- Last Round
- $33.9M Series BMar 2011
About
Omthera Pharmaceuticals was a Princeton, New Jersey-based specialty pharmaceutical company focused on developing new therapies for dyslipidemia — lipid disorders characterized by elevated triglycerides and increased cardiovascular risk. Founded in 2009, Omthera completed an IPO on Nasdaq (OMTH) in April 2013 and was subsequently acquired by AstraZeneca in August 2013 for approximately $323 million, giving AstraZeneca access to Epanova, a novel omega-3 carboxylic acid treatment for severe hypertriglyceridemia.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account